CRIS Current Research Information System

CIANI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.539
AS - Asia 5.520
EU - Europa 4.310
AF - Africa 512
SA - Sud America 223
OC - Oceania 5
Totale 16.109
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.473
IT - Italia 1.580
SG - Singapore 1.567
VN - Vietnam 1.510
CN - Cina 1.325
GB - Regno Unito 693
DE - Germania 493
HK - Hong Kong 405
SE - Svezia 286
IN - India 211
FR - Francia 208
NL - Olanda 208
BR - Brasile 150
IE - Irlanda 150
RU - Federazione Russa 137
SC - Seychelles 135
TG - Togo 134
KR - Corea 122
UA - Ucraina 120
CI - Costa d'Avorio 105
FI - Finlandia 82
JP - Giappone 76
CH - Svizzera 74
ZA - Sudafrica 73
JO - Giordania 53
BG - Bulgaria 51
ES - Italia 44
CA - Canada 42
EE - Estonia 40
PH - Filippine 40
TR - Turchia 38
NG - Nigeria 36
AR - Argentina 33
AT - Austria 33
ID - Indonesia 30
BE - Belgio 29
BD - Bangladesh 21
TH - Thailandia 21
PL - Polonia 18
IR - Iran 17
MX - Messico 16
TW - Taiwan 16
GR - Grecia 12
HR - Croazia 11
MY - Malesia 11
IQ - Iraq 10
DK - Danimarca 9
EC - Ecuador 9
PK - Pakistan 9
AE - Emirati Arabi Uniti 8
CL - Cile 7
SA - Arabia Saudita 7
VE - Venezuela 7
CO - Colombia 6
MA - Marocco 6
PE - Perù 6
RO - Romania 6
AU - Australia 5
CZ - Repubblica Ceca 5
LB - Libano 5
SM - San Marino 5
DZ - Algeria 4
NP - Nepal 4
PT - Portogallo 4
EG - Egitto 3
ET - Etiopia 3
KE - Kenya 3
PY - Paraguay 3
UZ - Uzbekistan 3
HU - Ungheria 2
IL - Israele 2
MD - Moldavia 2
NO - Norvegia 2
OM - Oman 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
GT - Guatemala 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
MU - Mauritius 1
MZ - Mozambico 1
NI - Nicaragua 1
PA - Panama 1
RE - Reunion 1
Totale 16.104
Salva come PNG Salva come JPEG
Città #
Singapore 1.167
Bologna 605
Ashburn 573
Chandler 543
Southend 504
Fairfield 503
Ho Chi Minh City 369
Hong Kong 363
Hanoi 331
Hefei 308
Santa Clara 297
San Jose 258
Houston 254
Wilmington 234
Woodbridge 227
Seattle 215
Ann Arbor 210
Cambridge 188
Beijing 165
Dublin 149
Dong Ket 144
Princeton 137
Lomé 134
Dallas 111
Seoul 109
Boardman 108
Abidjan 105
Los Angeles 79
Council Bluffs 75
Frankfurt am Main 74
Turin 72
Jacksonville 71
Lauterbourg 71
Milan 70
Bern 65
Helsinki 63
Nanjing 59
Tokyo 57
Bristol 55
Padova 55
Westminster 55
Amman 52
Falls Church 50
New York 50
Berlin 49
Sofia 49
Redmond 47
Buffalo 43
Da Nang 37
Haiphong 37
Rome 36
San Diego 36
Trento 36
Marano 34
Bengaluru 33
Munich 32
Abeokuta 31
Amsterdam 30
Islington 29
Shenyang 29
Brussels 28
Changsha 28
Tianjin 26
Guangzhou 25
Jinan 24
Argelato 23
Saint Petersburg 23
Redondo Beach 22
Johannesburg 21
Orem 21
Vienna 21
Hải Dương 20
Rimini 20
Shanghai 18
Mülheim 17
Nanchang 17
Chicago 16
Toronto 16
Biên Hòa 15
Bolzano 15
Bonn 15
Dearborn 15
Falkenstein 15
Hebei 15
Jakarta 15
Jerez De La Frontera 15
Pune 15
Redwood City 15
Wuhan 15
Bremen 14
Castel Maggiore 14
São Paulo 14
Des Moines 13
Istanbul 13
Modena 13
Florence 12
Mumbai 12
Quận Ba 12
Warsaw 12
Zhengzhou 12
Totale 10.664
Salva come PNG Salva come JPEG
Nome #
Inhibition of microglia over-activation restores neuronal survival and maturation in a mouse model of CDKL5 deficiency disorder 387
Age-related cognitive and motor decline in a mouse model of CDKL5 deficiency disorder is associated with increased neuronal senescence and death 338
CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder 333
Characterization of Perinatal Stem Cell Spheroids for the Development of Cell Therapy Strategy 326
Beneficial Antioxidant Effects of Coenzyme Q10 in In Vitro and In Vivo Models of CDKL5 Deficiency Disorder 324
First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease 289
Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder 288
Cardiac Functional and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder 283
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder 282
Functional impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder are ameliorated by a GABAB receptor antagonist 269
AR-A014418-based dual Glycogen Synthase Kinase 3β/Histone Deacetylase inhibitors as potential therapeutics for Alzheimer's disease 263
CDKL5 deficiency entails sleep apneas in mice 249
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder 248
Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder 247
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling (vol 29, pg 658, 2019) 247
Artificial protein and its applications 242
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder 240
Treatment with a GSK-3β/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder 234
Dietary restriction differentially protects from neurodegeneration in animal models of excitotoxicity. 233
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons 231
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder 227
Treatment with FRAX486 rescues neurobehavioral and metabolic alterations in a female mouse model of CDKL5 deficiency disorder 219
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome 219
Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome 218
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? 215
The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for down syndrome. 213
Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells. 212
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells 212
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome 211
Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice 206
APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. 205
Functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder are rescued by a TrkB agonist 205
Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder 202
Neurochemical correlates of nicotine neurotoxicity on rat habenulo-interpeduncular cholinergic neurons. 201
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder 200
APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. 198
Postnatal neurogenesis in the dentate gyrus of the guinea pig 197
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome 197
Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. 195
Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder 195
Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice 193
Voluntary Running Improves Behavioral and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder 185
Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. 185
Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn Mouse, an animal model for Down syndrome. 183
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome 182
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome 181
Sex differences in the stereological parameters of the hippocampal dentate gyrus of the guinea pig before puberty 175
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. 175
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo 170
Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period. 168
Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression 167
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome 167
Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. 164
Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat. 161
Effect of early isolation on signal transfer in the entorhinal cortex-dentate-hippocampal system 159
Timing of therapies for downsyndrome: The sooner, the better 159
Mapping pathological phenotypes in a mouse model of CDKL5 disorder. 157
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. 157
CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/GSK-3{beta}/{beta}-catenin signaling 157
The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases 156
Sex differences in the hilar mossy cells of the guinea-pig before puberty. 155
Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. 149
Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation. 146
Characterisation of sleep apneas and respiratory circuitry in mice lacking CDKL5 144
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome 144
Is it possible to improve neurodevelopmental abnormalities in Down syndrome? 142
Updating the dual role of brain nitric oxide in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. 137
Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig. 137
Lactic acid bacteria as microbial cell factories for the in vivo delivery of therapeutic proteins as secretable TAT fusion products 136
Site-specific abnormalities in the visual system of a mouse model of CDKL5 deficiency disorder 135
null 130
Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation. 127
Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder 124
Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome 124
Design, synthesis and pharmacological evaluation of multitarget GPR40 agonists/HDAC6 inhibitors for Alzheimer's disease 118
Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down sindrome 114
TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF 113
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder 112
null 100
null 97
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. 96
Adult-Onset Deletion of CDKL5 in Forebrain Glutamatergic Neurons Impairs Synaptic Integrity and Behavior in Mice 94
Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome 89
Autistic-relevant behavioral phenotypes of a mouse model of cyclin-dependent kinase-like 5 deficiency disorder 75
Sex differences in the hippocampal dentate gyrus of the guinea-pig before puberty 73
Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency 65
Effects of gestational or neonatal treatment with alpha-difluoromethylornithine on ornithine decarboxylase and polyamines in developing rat brain and on adult rat neurochemistry 49
Sex differences in the hilar mossy cells of the guinea-pig before puberty 45
Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: Implication for a survival role of nitric oxide 44
A cross-correction gene therapy approach for CDKL5 deficiency disorder improves the pathological phenotype of CDD patient-derived cortical organoids 39
Totale 16.354
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.931
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.931
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021493 0 0 0 0 0 0 0 0 0 98 53 342
2021/20221.475 99 71 117 117 135 102 62 80 71 107 261 253
2022/20232.213 173 366 105 260 162 196 55 125 365 51 166 189
2023/2024797 58 83 37 85 49 135 88 70 50 40 42 60
2024/20252.529 139 289 183 211 397 161 154 95 90 228 142 440
2025/20265.775 502 840 526 475 689 306 766 249 1.113 309 0 0
Totale 16.354